Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of CH5-HK H5N1 vaccine immunogenicity and safety in unvaccinated healthy adults
jRCT2031250664Phase 2Active, not recruiting
- Sponsor
- AMED SCARDA
- Start
- Mar 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CH5-HK H5N1 avian influenza vaccine in Avian influenza A H5 subtype (H5) and influenza, sponsored by AMED SCARDA. Primary endpoint: Immunogenicity against A/H5 subtype avian influenza virus. Started Mar 2026; status: active, not recruiting.
02
Drugs
CH5-HK H5N1 avian influenza vaccine
03
Conditions
Avian influenza A H5 subtype (H5)influenza
Beyond the preview
Go deeper on jRCT2031250664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250664.